OCA at 16:28, 18 October 2023

OCA — Wed, 18 Oct 2023 16:28:47 GMT

←Older revision		Revision as of 16:28, 18 October 2023
Line 1:		Line 1:

-	====	+	==Crystal structure of human TGF-beta-2 bound to 4A11.V2 Fab==
-	<StructureSection load='7rco' size='340' side='right'caption='[[7rco]]' scene=''>	+	<StructureSection load='7rco' size='340' side='right'caption='[[7rco]], [[Resolution\|resolution]] 2.90Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id= OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol= FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[7rco]] is a 6 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=7RCO OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=7RCO FirstGlance]. <br>
-	</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7rco FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7rco OCA], [https://pdbe.org/7rco PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7rco RCSB], [https://www.ebi.ac.uk/pdbsum/7rco PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7rco ProSAT]</span></td></tr>	+	</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models\|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution\|Resolution]] 2.9Å</td></tr>
		+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7rco FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7rco OCA], [https://pdbe.org/7rco PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7rco RCSB], [https://www.ebi.ac.uk/pdbsum/7rco PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7rco ProSAT]</span></td></tr>
	</table>		</table>
		+	== Disease ==
		+	[https://www.uniprot.org/uniprot/TGFB2_HUMAN TGFB2_HUMAN] Note=A chromosomal aberration involving TGFB2 is found in a family with Peters anomaly. Translocation t(1;7)(q41;p21) with HDAC9. Defects in TGFB2 are the cause of Loeys-Dietz syndrome 4 (LDS4) [MIM:[https://omim.org/entry/614816 614816]. An aortic aneurysm syndrome with widespread systemic involvement. LDS4 is characterized by arterial tortuosity, aortic dissection, intracranial aneurysm and subarachnoid hemorrhage, hypertelorism, bifid uvula, pectus deformity, bicuspid aortic valve, arachnodactyly, scoliosis, foot deformities, dural ectasia, joint hyperflexibility, and thin skin with easy bruising and striae.<ref>PMID:22772368</ref>
		+	== Function ==
		+	[https://www.uniprot.org/uniprot/TGFB2_HUMAN TGFB2_HUMAN] TGF-beta 2 has suppressive effects on interleukin-2 dependent T-cell growth.
		+	<div style="background-color:#fffaf0;">
		+	== Publication Abstract from PubMed ==
		+	Antibody function is typically entirely dictated by the Complementarity Determining Regions (CDRs) that directly bind to the antigen, while the framework region acts as a scaffold for the CDRs and maintains overall structure of the variable domain. We recently reported that the rabbit monoclonal antibody 4A11 (rbt4A11) disrupts signaling through both TGFbeta2 and TGFbeta3 (Sun et al. in Sci Transl Med, 2021. https://doi.org/10.1126/scitranslmed.abe0407 ). Here, we report a dramatic, unexpected discovery during the humanization of rbt4A11 where, two variants of humanized 4A11 (h4A11), v2 and v7 had identical CDRs, maintained high affinity binding to TGFbeta2/3, yet exhibited distinct differences in activity. While h4A11.v7 completely inhibited TGFbeta2/3 signaling like rbt4A11, h4A11.v2 did not. We solved crystal structures of TGFbeta2 complexed with Fab fragments of h4A11.v2 or h4A11.v7 and identified a novel interaction between the two heavy chain molecules in the 2:2 TGFb2:h4A11.v2-Fab complex. Further characterization revealed that framework residue variations at either position 19, 79 or 81 (Kabat numbering) of the heavy chain strikingly converts h4A11.v2 into an inhibitory antibody. Our work suggests that in addition to CDRs, framework residues and interactions between Fabs in an antibody could be engineered to further modulate activity of antibodies.
		+
		+	Dramatic activation of an antibody by a single amino acid change in framework.,Liang WC, Yin J, Lupardus P, Zhang J, Loyet KM, Sudhamsu J, Wu Y Sci Rep. 2021 Nov 16;11(1):22365. doi: 10.1038/s41598-021-01530-w. PMID:34785671<ref>PMID:34785671</ref>
		+
		+	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
		+	</div>
		+	<div class="pdbe-citations 7rco" style="background-color:#fffaf0;"></div>
		+
		+	==See Also==
		+	*[[Antibody 3D structures\|Antibody 3D structures]]
		+	== References ==
		+	<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
		+	[[Category: Homo sapiens]]
	[[Category: Large Structures]]		[[Category: Large Structures]]
-	[[Category: ~~Z-disk~~]]	+	[[Category: Lupardus PJ]]
		+	[[Category: Sudhamsu J]]
		+	[[Category: Yin J]]

OCA at 08:51, 29 September 2021

OCA — Wed, 29 Sep 2021 08:51:50 GMT

←Older revision		Revision as of 08:51, 29 September 2021
Line 1:		Line 1:
-	'''Unreleased structure'''

-	~~The entry~~ 7rco ~~is ON HOLD until Paper Publication~~	+	====
-		+	<StructureSection load='7rco' size='340' side='right'caption='[[7rco]]' scene=''>
-	~~Authors~~:	+	== Structural highlights ==
-		+	<table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id= OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol= FirstGlance]. <br>
-	~~Description~~:	+	</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7rco FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7rco OCA], [https://pdbe.org/7rco PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7rco RCSB], [https://www.ebi.ac.uk/pdbsum/7rco PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7rco ProSAT]</span></td></tr>
-	[[Category: ~~Unreleased~~ Structures]]	+	</table>
		+	__TOC__
		+	</StructureSection>
		+	[[Category: Large Structures]]
		+	[[Category: Z-disk]]

OCA at 09:19, 4 August 2021

OCA — Wed, 04 Aug 2021 09:19:27 GMT

←Older revision		Revision as of 09:19, 4 August 2021
Line 1:		Line 1:
	'''Unreleased structure'''		'''Unreleased structure'''

-	The entry 7rco is ON HOLD	+	The entry 7rco is ON HOLD until Paper Publication

	Authors:		Authors:

OCA: Protected "7rco" [edit=sysop:move=sysop]

OCA — Wed, 14 Jul 2021 08:58:04 GMT

Protected "7rco" [edit=sysop:move=sysop]

←Older revision

Revision as of 08:58, 14 July 2021

OCA: New page: '''Unreleased structure''' The entry 7rco is ON HOLD Authors: Description: Category: Unreleased Structures

OCA — Wed, 14 Jul 2021 08:58:03 GMT

New page: '''Unreleased structure''' The entry 7rco is ON HOLD Authors: Description: Category: Unreleased Structures

New page

'''Unreleased structure'''

The entry 7rco is ON HOLD

Authors:

Description:
[[Category: Unreleased Structures]]

7rco - Revision history

OCA at 16:28, 18 October 2023

OCA at 08:51, 29 September 2021

OCA at 09:19, 4 August 2021

OCA: Protected "7rco" [edit=sysop:move=sysop]

OCA: New page: '''Unreleased structure''' The entry 7rco is ON HOLD Authors: Description: Category: Unreleased Structures